ReviewArchives of dermatological research2021
Reporting regression with melanoma in situ: reappraisal of a potential paradox.
Review in Archives of dermatological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Is It Time to Supersede the Diagnostic Term "Melanoma In Situ with Regression?" A Narrative Review.Dermatopathology (Basel, Switzerland) · 2023Review
- Thin and in situ melanoma: an update for the dermatologist.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma in situ (MIS) is a form of radial growth phase melanoma in which the proliferation of malignant cells is confined to the epidermis. Histologic features are invaluable in recognition of MIS. Regression occurs when the host's immune system attacks the primary melanocytic tumor cells via tumor infiltrate lymphocytes, resulting in a fibrotic component. Various criteria have been proposed to assess the extent of histologic regression. Some authors define regression based on histologic features of the dermis, which is inappropriate for MIS. Specific dermatoscopic findings of regression in MIS have been reported including peppering, grey-blue areas, white areas, and blue-whitish veils. Many studies assess the impact of histologic regression on invasive melanoma prognosis, but no studies to-date have considered the effect of histologic regression exclusively in patients with MIS. The literature to-date does not suggest evaluation and management should be modified if histologic regression is present in MIS. Studies specifically investigating the effect of histologic regression on MIS prognosis are needed to inform evidence-based practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.